Related to CHMP Says AMT’s Lipoprotein Lipase Deficiency Candidate Can’t Yet Be Approved

• Feature Articles: Uncertainty Persists with RUO Products
  
• Legal Affairs: HHS Puts Stamp on Personalized Medicine
  
• Feature Articles: Draft Guidance for RUO Products Issued
  
• Feature Articles: Engineering Regenerative Medicine's Future
  
• Point of View: T-Cell Therapy Eradicates CLL in Trial
  
• Point of View: FDA Thumps Industry, Patients Feel the Pain
  
• Feature Articles: Assessing the Impact of Biotech Regulation
  
• Feature Articles: The History and Promise of Gene Therapy
  
• Point of View: Driving Down Medical and Healthcare Spending
  
• Feature Articles: USP Improves Biologic Quality Standards
  
• Feature Articles: Gene Therapy Briefs
  
• Gene Therapy Briefs: Gene Therapy Briefs
  
• Gene Therapy Briefs: Gene Therapy Briefs
  
• BioMarket Trends: FDA Releases Biosimilars Guidelines to Little Fanfare
  
• Gene Therapy Briefs: Gene Therapy Briefs
  
• BioMarket Trends: Regulatory Environment Warms Up to Obesity Drugs
  
• Gene Therapy Briefs: Gene Therapy Briefs
  
• Gene Therapy Briefs: Gene Therapy Briefs
  
• Feature Articles: Proposed Standards for Immunogenicity Testing
  
• Gene Therapy Briefs: Gene Therapy Briefs